Filing Flows › Recursion Pharmaceuticals (RXRX) › Q3 2025
Recursion Pharmaceuticals (RXRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Recursion Pharmaceuticals (RXRX) reported revenue of $5.2M for the third quarter 2025 (Q3 2025), -80% from a year earlier and -73% from the quarter before.
Recursion Pharmaceuticals, Q3 2025: revenue $5.2M (-80% year over year), net loss $162M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.2M | -73% | -80% |
| Operating profit | −$172M | — | — |
| Net earnings | −$162M | — | — |
| Operating cash flow | −$117M | — | — |
What changed
Revenue was $5.2M in Q3 2025, down 80% year over year and down 73% from the previous quarter. Operating revenue was the largest line at 96% of revenue. Operating revenue lost $21.1M year over year (down 81%), 101% of the total change.
Operating costs exceeded revenue by $172.2M, an operating margin of -3327.6%. Total costs grew 43% against a revenue fall of 80%. The fastest-growing cost line was Research & development (+62%). The quarter ended with a net loss of $162.3M, narrower than the previous quarter's $171.9M loss.
Operating cash flow was −$117.4M. Non-cash charges added back $21.0M of depreciation and amortization and $25.2M of share-based compensation. Capital expenditures of $243K exceeded it, leaving free cash flow of −$117.6M.
Questions
What was Recursion Pharmaceuticals' revenue in the third quarter 2025?
Recursion Pharmaceuticals (RXRX) reported revenue of $5.2M for the third quarter 2025 (Q3 2025), -80% from a year earlier and -73% from the quarter before.